Glucose is the main source of energy in the brain; however, glycogen is not stored in neurons and is present only in astroglial cells 1 . Nevertheless, in several pathologies, polymers of glucose, normally referred to as polyglucosan bodies, accumulate in neuronal tissue 2 . One such pathology is Lafora-type progressive myoclonus epilepsy [3] [4] [5] (EPM2, OMIM 254780). The hallmark of Lafora disease is the presence of large inclusions (Lafora bodies) in the axons and dendrites of neurons 6, 7 . These inclusions are composed of poorly branched polymers of glucose, which can be considered to be abnormal glycogen molecules. However, the mechanism by which polyglucosan bodies accumulate in Lafora disease remains unknown. Lafora disease typically manifests during adolescence with generalized tonic-clonic seizures, myoclonus, absences, drop attacks or partial visual seizures. As the disease progresses, afflicted individuals suffer a rapidly progressive dementia with apraxia, aphasia and visual loss, leading to a vegetative state and death, usually in the first decade from the onset of the initial symptoms. Seizures are commonly the first manifestation of the disease and may be generalized (tonic-clonic, absences, myoclonic, tonic or atonic) or focal (usually with visual symptoms). Electroencephalograms show both generalized and focal epileptiform discharges [8] [9] [10] [11] [12] [13] .
Lafora disease is inherited as an autosomal recessive disorder and shows genetic heterogeneity. It has been associated with mutations in two genes. Epilepsy, progressive myoclonus 2a (EPM2A) is mutated in approximately 48% of individuals with Lafora disease and encodes laforin, a dual-specificity protein phosphatase with a functional carbohydrate-binding domain [14] [15] [16] [17] [18] . A second gene, Epilepsy, progressive myoclonus 2b (EPM2B), is mutated in 30-40% of those with Lafora disease and encodes malin, an E3 ubiquitin ligase [18] [19] [20] . Malin interacts with laforin and causes its ubiquitination 20 . Individuals with mutations in laforin or malin are neurologically and histologically indistinguishable, which strongly suggests that these two proteins operate through common physiological pathways 18 .
To examine how defects in either laforin or malin contribute to the formation of Lafora bodies, we have examined their role in neurons. We show that the laforin-malin complex blocks glycogen synthesis in these cells by inducing the proteasome-dependent degradation of MGS and PTG.
RESULTS

Neurons keep the machinery for glycogen synthesis inactive
Analysis of whole mouse brain, differentiated mouse Neuro2a (N2a) cells and primary cultured mouse neurons showed that neurons express MGS (Fig. 1a,b) . Expression of the liver glycogen synthase (LGS) isoform was absent in these specimens ( Fig. 1a and data not shown). Furthermore, neurons did not express glycogen phosphorylase, the enzyme that is responsible for the degradation of this polysaccharide (Fig. 1b) . Notably, despite the expression of MGS, neurons and N2a cells did not accumulate detectable amounts of glycogen when cultured in medium containing high concentrations of glucose (30 mM) (Fig. 1c) . In contrast, astrocytes grown under the same conditions showed marked accumulation of this polysaccharide ( Fig. 1c; see ref. 1 ).
The inability of neurons to synthesize glycogen could be a consequence of a lack of sufficient intracellular concentrations of glucose-6-phosphate (G6P), the metabolite required for the activation of MGS [21] [22] [23] , or of sufficient amounts of MGS in this cell type. However, a fivefold increase in the amount of intracellular G6P in primary cultured neurons by overexpression of glucokinase or hexokinase I did not result in glycogen synthase activation or glycogen accumulation (Fig. 2a) . Similarly, overexpression of MGS in primary cultured neurons using recombinant adenoviruses did not increase glycogen deposition (Fig. 2b,c) . These results indicate that the lack of glycogen accumulation in these cells was not a result of low levels of MGS or G6P. Similar results were obtained in N2a cells ( Supplementary Fig. 1 online). MGS expressed in neurons localized mostly in the nucleus (Fig. 2c, upper) , which is a characteristic of cells that are depleted of glycogen 24, 25 . In contrast, MGS in astrocytes clustered in the cytoplasm, which is a typical location for this protein under conditions of active glycogen synthesis (Fig. 2c, lower) .
Control of glycogen synthesis is achieved mainly through the inactivation of MGS by phosphorylation of multiple serine residues at the C and N termini by a range of kinases 26 . Western blot analysis showed that MGS in primary cultured neurons and N2a cells was phosphorylated at the Ser640 and Ser7/10 residues, the phosphorylation sites that reduce the activity of the enzyme the most 26 ( Fig. 2d and Supplementary Fig. 1 ). However, Ser640 can be effectively dephosphorylated by treating neurons with 20 mM LiCl (Fig. 2e) , a glycogen synthase kinase 3 inhibitor 27 . Concomitantly, dephosphorylated MGS altered its subcellular localization and accumulated at specific sites in the cytoplasm, coinciding with growing glycogen particles (Fig. 2c , middle panel and Supplementary Fig. 1 ). Incubation of primary cultured neurons with LiCl at therapeutic concentrations (1-2 mM) for up to 48 h did not produce any substantial effect on MGS.
Extensive MGS dephosphorylation at Ser640 and Ser7/10 was induced in primary cultured neurons and N2a cells by PTG ( Fig. 3a and Supplementary Fig. 1 ), a regulatory subunit of protein phosphatase 1 that promotes the activation of MGS [28] [29] [30] and that interacts with laforin 31 . This dephosphorylation was accompanied by a marked increase in glycogen accumulation throughout the soma, neurites and axons (Fig. 3b,c and Supplementary Fig. 1 ). Like LiCl, PTG induced the intracellular relocation of MGS, which became clustered in the cytoplasm, colocalizing with glycogen particles (data not shown). The activation state of MGS increased in neurons overexpressing PTG, reaching values that were close to those of full activation ( Fig. 3b and Supplementary Fig. 1 ), and the enzyme showed increased electrophoretic mobility, which is characteristic of the activated (dephosphorylated) enzyme ( Fig. 3a and Supplementary Fig. 1 ). Taken together, these findings demonstrate that neurons have the appropriate machinery to synthesize glycogen, but this system is essentially blocked by keeping MGS in a phosphorylated, inactive state. In this context, it is of interest that PTG is scarcely expressed in neurons 32 . The PTG-MGS transcript ratio was approximately 20-fold lower in neurons than in cells that normally accumulate glycogen (Fig. 3d) . Because Lafora bodies are composed of poorly branched glucose polymers, we complexed samples isolated from neuronal cells with iodine and recorded the spectra, as described 33 , to measure the degree of ramification of the glycogen produced in the experiments described above. Shifting of the absorption maximum to a higher wavelength is indicative of less branching. Normal glycogen gave a peak at 483 nm, whereas that isolated from N2a or primary cultured neurons peaked at 511 nm, indicating that it was poorly branched.
Glycogen accumulation is pro-apoptotic in neuronal cells
To ascertain whether accumulation of this poorly branched glycogen causes alterations in neuronal cells, we examined whether apoptotic markers were present in primary cultured neurons that were forced to accumulate glycogen by overexpression of PTG. Glycogen-accumulating primary cultured neurons showed increased apoptosis compared with controls when measured by TUNEL staining (Fig. 4a ) and active caspase-3 assays (Fig. 4b,c) . In contrast, astrocytes expressing the same amount of PTG, and therefore synthesizing high levels of glycogen, did not show an activation of caspase-3 (Fig. 4c) . Therefore, glycogen deposition triggered apoptosis specifically in cultured neurons.
The laforin-malin complex downregulates glycogen synthesis To determine the role of laforin and malin in the generation of Lafora bodies, we analyzed whether these proteins have the capacity to modulate the PTG-induced accumulation of glycogen in neuronal cells. When laforin and malin were separately coexpressed with PTG in these cells, we did not observe an effect on PTG-induced glycogen accumulation ( Fig. 5a and Supplementary Fig. 2 online) . However, when both laforin and malin were coexpressed simultaneously with PTG, they completely blocked the activation of glycogen synthesis ( Fig. 5a and Supplementary Fig. 2 ). In addition, we detected a marked reduction of MGS and PTG levels ( Fig. 5b and Supplementary Fig. 2 ). The levels of laforin were also diminished, although to a lesser extent (Fig. 5b) . In contrast, the amount of malin was substantially increased when it was coexpressed with laforin, suggesting that malin is stabilized by laforin. Therefore, malin levels were inversely correlated with those of MGS, PTG and laforin (Fig. 5b) . The reduction of MGS protein levels was correlated with a sixfold decrease in MGS activity in cells expressing both laforin and malin compared with cells expressing laforin alone (Fig. 5c) . The effects of malin and laforin on MGS and PTG were specific, as other proteins involved in glycogen metabolism, such as hexokinase I or glycogen synthase kinase 3, were not degraded by the combined action of laforin and malin (data not shown). The proteasome inhibitors MG-132 and lactacystin 34 blocked the decrease of MGS, PTG and laforin levels that was induced by the malin-laforin complex ( Fig. 5d and Supplementary Fig. 2 ). Quantitative real-time PCR (RT-PCR) analysis confirmed that MGS, laforin and PTG transcript levels were unaffected, indicating that the changes in MGS and PTG protein levels were a consequence of protein degradation through the ubiquitin-proteasome pathway and were not caused by alterations at the transcription level (data not shown). These data suggest that the laforin-malin complex is important in the modulation of MGS and PTG levels. Proteasome-dependent degradation of laforin, together with PTG and MGS, may act as a safety switch; that is, when laforin levels are reduced, no laforin-malin complexes are formed, and therefore MGS and PTG degradation will not occur. In addition, the amount of malin expressed in the absence of laforin was higher when these proteasome inhibitors were present. This observation suggests that malin is also degraded through the ubiquitin-proteasome pathway (Fig. 5d) .
In a survey of individuals with Lafora disease, we identified a malin mutation (D146N) that specifically disrupts the interaction between laforin and malin without altering the E3 ubiquitin ligase activity of the latter (M.C. Solaz-Fuster, J.V. Gimeno-Alcañiz, S.R., M.E. (Fig. 6a) and, in contrast to wild-type malin, failed to induce the degradation of MGS and PTG (Fig. 6b) . Therefore, the malin-laforin interaction is crucial for the action of these two proteins on neuronal glycogen metabolism.
If laforin and malin are required to decrease the levels of MGS and PTG, the absence of these proteins in individuals with Lafora disease should result in increased MGS and PTG levels. To test this, we mimicked the pathological condition by silencing laforin expression in neuronal cells using short interfering RNA (siRNA) oligonucleotides (Fig. 6c) . The knockdown of laforin by two distinct siRNAs caused a marked increase in MGS and PTG levels compared with those in cells transfected with control siRNA (Fig. 6d,e) . More glycogen accumulated in these cells under glycogenic conditions (Fig. 6f) . These results establish the involvement of the laforin-malin system in the control of MGS and PTG stability and glycogen synthesis.
DISCUSSION
Our findings demonstrate the existence of a previously unknown regulatory mechanism for glycogen accumulation in neurons, which operates through the proteasome-mediated degradation of both MGS and PTG, with the latter being the key protein for MGS activation (see schematic in Supplementary Fig. 3 online) . MGS is a highly regulated enzyme. It is activated by G6P and inactivated by phosphorylation at multiple sites 35 . Furthermore, it is also regulated by changes in its subcellular localization in response to the metabolic status of the cell 24 . The mechanism demonstrated here, mediated by the laforin-malin complex, represents an additional control step that is superimposed on A R T I C L E S the previously known ones described above, and adds a further level of complexity to the control of glycogen synthesis. Although prevalent in neurons, this mechanism is probably involved in the regulation of glycogen synthesis more generally, as laforin and malin are not restricted to neurons. This mechanism probably serves to prevent excessive glycogen accumulation in certain tissues or under specific physiological conditions. Furthermore, we demonstrate here that, against general belief, neurons have the machinery to synthesize glycogen, but this capacity is silenced by the inactivation of neuronal MGS through extensive phosphorylation and by the mechanism described here, which further ensures the blockage of glycogen synthesis by degrading both MGS and PTG. Altogether, these apparently redundant control mechanisms for glycogen synthesis may reflect the need to prevent glycogen accumulation in neurons. Neurons do not express detectable amounts of glycogen phosphorylase, the key enzyme for glycogen degradation. Therefore, the degradation of glycogen, should it accumulate, would not be feasible. Furthermore, when MGS becomes active, neurons accumulate poorly branched glycogen (polyglucosan). This observation illustrates the necessity of strictly controlling MGS activity in neurons.
As we have shown, deposition of this poorly branched glycogen is associated with deleterious effects in neuronal cells, as it activates the apoptotic program. Consequently, the previously unknown regulatory mechanism for glycogen synthesis that we report here is probably critical for preventing the accumulation of a dangerous molecule in the cytoplasm of neurons. Disturbance of this mechanism, as a consequence of loss-of-function mutations in laforin or malin, would explain the accumulation of intracellular inclusion bodies of glycogen-like composition in neurons (and in other cell types). We do not know the extent to which this phenomenon may be responsible for the cardinal clinical manifestations of Lafora disease. Although our results are consistent with the hypothesis that glycogen deposition triggers the alterations of neuronal function in Lafora disease, we cannot exclude the possibility that other potential targets of the laforin-malin complex are also involved in the pathogenesis of this disease. Whether this complex also triggers the degradation of other proteins is unknown.
In addition, our results raise the question of why neurons have maintained MGS expression throughout evolution if it must be kept strictly inactive under normal conditions. One possibility is that the genomic structure of the MGS gene (Gys1) does not allow for the silencing of MGS expression in neurons without interfering with the expression of other relevant neuronal genes or with the expression of MGS in other cell types. Alternatively, MGS may have a second, as yet undiscovered, fundamental function in neurons.
METHODS
Primary cultures of neurons and astrocytes. We obtained telencephalic neuron cultures from mouse embryos at embryonic day 16 (OF1 mice, Charles River Laboratories) as described 36 (Supplementary Methods online) . These experiments were approved by the Barcelona Science Park's Animal Experimentation Committee and were carried out in accordance with the European Community Council Directive and the US National Institutes of Health guidelines for the care and use of laboratory animals. Enzymes and biochemical reagents were from Sigma, unless otherwise indicated. All other chemicals were of analytical grade. We cultured cells in serum-free Neurobasal medium (Invitrogen) supplemented with 2 mM L-glutamine (Invitrogen), 30 mM D-glucose, 5 mM NaHCO 3 (Invitrogen), penicillin (100 U ml -1 , Invitrogen), streptomycin (100 mg ml -1 , Invitrogen) and B27 supplement diluted 1:50 (Invitrogen). After 1 d of culture, we treated cells with uridine (50 mg ml -1 ) and 5-fluoro-2¢-deoxyuridine (20 mg ml -1 ) to minimize the contamination by astrocytes. Primary cultures of neurons were infected at 5 d in culture for 12 h with adenoviruses at diverse multiplicities of infection (MOI) depending on the experiments. After removal of the virus-containing media, infected cells were maintained for 48 h in neuronal culture medium. For primary cultures of astrocytes, we cultured dissociated cells in Neurobasal medium supplemented with 2 mM L-glutamine, 30 mM D-glucose, 5 mM NaHCO 3 , penicillin (100 U ml -1 ), streptomycin (100 mg ml -1 ), 5% horse serum and 5% fetal bovine serum (FBS). Primary cultures of astrocytes were incubated for 2 h with adenoviruses at diverse MOIs. After removal of the virus-containing media, astrocytes were incubated for 48 h with astrocyte culture medium. 2 mM L-glutamine, 25 mM D-glucose, penicillin (100 U ml -1 ), streptomycin (100 mg ml -1 ) and 10% FBS. Cells differentiated after being cultured for 72 h in FBS-free DMEM (with supplements). N2a cells were incubated for 2 h with adenoviruses at various MOIs. After removal of the virus-containing media, N2a cells were incubated for 48 h with N2a differentiation medium.
Preparation of recombinant adenovirus. Recombinant adenoviruses coding for rat liver glucokinase (AdCMV-GK) 37 , rat liver hexokinase I (AdCMV-HKI) 37 , green fluorescent protein (GFP) (AdCMV-GFP) 22 , human MGS (AdCMV-MGS) 22 and human MGS fused to GFP (AdCMV-GFP-MGS) 25 have been described. We generated recombinant adenoviruses coding for the mouse PTG fused to GFP (AdCMV-PTG), human laforin (AdCMV-laf), wild-type (wt) human malin (AdCMV-malin) and mutant D146N human malin (AdCMV-malinD146N) fused to hemagglutinin epitope (HA). We obtained the coding sequence for PTG by amplification of mouse hepatocyte genomic DNA using the oligonucleotide primers 5¢-CCG AAT TCG GNA CGA GAT GTG CTA GAT CC-3¢ and 5¢-CGC CAG TGT GCT GGA ATT CTC AAG TAG-3¢. The coding sequence for PTG was then ligated into the pEGFP-C1 vector (Clontech), which was previously digested with BglII. The generation of the pCINeo-Laforin vector was described previously 31 . The coding sequence of human malin was amplified from human spleen genomic DNA by PCR using the oligonucleotide primers 5¢-GGA TCC TAT GGC GGC CGA AGC-3¢ and 5¢-GAG ATC TCA CAA TTC ATT AAT GGC AGA C-3¢, and was cloned into the mammalian expression vector pcDNA3, which contained an N-terminal HA tag. This pcDNA3-Malin wt-HA vector was used as the template for the introduction of mutation D146N by PCR, using the QuikChange Site-Directed Mutagenesis Kit (Stratagene). Then pEGFP-PTG, pCINeo-Laforin, pcDNA3-Malin wt-HA and pcDNA3-Malin D146N-HA vectors were used as templates for subcloning all of the selected cDNAs into the pAC.CMVpLpA plasmid 38 using the BD In Fusion PCR Cloning kit (Clontech) and appropriate oligonucleotides (5¢-CGA GCT CGG TAC CCG GGA TAC CAC CAT GGC C-3¢ and 5¢-CTG CAG GTC GAC TCT AGA TCA GCG AGC TCT AG-3¢ for laforin, 5¢-CGA GCT CGG TAC CCG GGC GAC TCA CTA TAG GC-3¢ and 5¢-CTG CAG GTC GAC TCT AGT CGA CTC TAG ACC AG-3¢ for wt malin-HA and malin D146N-HA, and 5¢-CGA GCT CGG TAC CCG GGC GGG TAC CGG TCG CC-3¢ and 5¢-AAG CTA TAG CTA CTT GCT AGA GTC GAC CTG CAG-3¢ for PTG-GFP).
To obtain the infective particles, human kidney 293 cells (cultured in DMEM supplemented with 10% FBS) were cotransfected with pAC.CMV plasmids containing the PTG-GFP, laforin, wt malin-HA or malin D146N-HA cDNAs and the pJM17 plasmid 39 , and then amplified 38 . We confirmed the absence of errors by extracting and sequencing viral DNA 38 from all of the adenoviruses generated.
RNA interference. We used two independent siRNAs to target laforin: laforin siRNA 1 (Ambion, predesigned siRNA#16708: sense, 5¢-GCA CAA CAA GAC UUU UCU Ctt-3¢, and antisense, 5¢-GAG AAA AGU CUU GUU GUG Ctt-3¢) and laforin siRNA 2 (Custom SMARTpool siRNA designed to target laforin, Dharmacon). We used GAPDH human, mouse and rat siRNAs as positive controls and Negative Control #1 siRNA (Ambion, catalog #4624) as a negative control. We transfected a concentration of 100 nM of each siRNA into N2a cells using Lipofectamine 2000 (Invitrogen), following the manufacturer's instructions. We measured the efficiency of laforin knockdown by RT-PCR analysis.
Electrophoresis and immunoblotting. Cell-culture plates were processed for protein extract preparation (Supplementary Methods). Proteins were resolved by 10% SDS-PAGE, transferred onto a nitrocellulose membrane (Schleicher and Schuell) and probed with the following antibodies: rabbit antibody to human MGS (MGS3), which recognizes MGS independently of its phosphorylation state 25 , sheep antibody to MGS phosphorylated on Ser7 and 10 (PGSser7/10, a gift from D.G. Hardie, University of Dundee, UK) 40 , rabbit antibody to MGS phosphorylated on Ser640 (PGSser641, Cell Signaling), rabbit antibody to glial fibrillary acidic protein (GFAP, DakoCytomation), rabbit antibody to GFP (Immunokontact), mouse antibody to b-actin, mouse antibody to HA and mouse antibody to laforin. Antibody to brain glycogen phosphorylase was produced by Eurogentec: chickens were immunized against a peptide at the C terminus (GVEPSDLQIPPPNLPKD, amino acids 826-842) of mouse brain glycogen phosphorylase. For further details about the secondary antibodies used in this study see the Supplementary Methods.
Immunocytochemistry. Cells seeded on poly-L-lysine-coated coverslips were fixed for 30 min in PBS containing 4% (w/v) paraformaldehyde. After fixation, cells were incubated with NaBH 4 (1 mg ml -1 ) for 10 min and permeabilized for 20 min with PBS containing 0.2% (v/v) Triton X-100. Blocking and incubation with the primary and secondary antibodies were carried out as previously described 25 . Coverslips were washed, air-dried and mounted onto glass slides using Mowiol as mounting medium. We used primary antibodies to MGS3 and GFAP, mouse antibody to b-III-tubulin (TUJ1) and a monoclonal antibody against glycogen (a gift from O. Baba, Tokyo Medical and Dental University) 41 . In some cases, nuclei were stained with Hoechst 33342 (Molecular Probes). For information about the secondary antibodies used, see the Supplementary Methods. Fluorescence images were obtained with a Leica SPII Spectral microscope (Leica Lasertechnik). The light source was an argon/krypton laser (75 mW), and optical sections (0.1 mm) were obtained.
Apoptosis assays. Neurons seeded onto poly-L-lysine-coated coverslips were fixed for 30 min in PBS containing 4% (w/v) paraformaldehyde and processed for TUNEL or active caspase-3 staining. TUNEL assays were carried out using the ApopTag Peroxidase in situ Apoptosis Detection Kit (Chemicon), following the manufacturer's instructions. Active caspase-3-positive cells were visualized by immunocytochemistry using the cleaved caspase-3 antibody (Cell Signaling) (Supplementary Methods). The TUNEL-and active caspase-3-positive cells were photographed with a Nikon Eclipse E-600 microscope using a 40Â objective. The percentage of positive cells was estimated in 8-14 fields from each of three coverslips (three independent experiments) for each treatment condition (500-600 total cells). Total number of cells was evidenced after staining of nuclei with Hoechst 33342.
RNA purification and retro-transcription. Total RNA was isolated from mouse tissue and reverse transcribed as described in the Supplementary Methods. A series of specific primers were designed to specifically amplify a fragment of the coding sequence of mouse MGS, LGS and GFAP (Supplementary Methods).
Quantitative RT-PCR. We followed the standard RT-PCR protocol of the ABI Prism 7700 Detection System, together with the ready-made TaqMan primer and probe sets (Applied Biosystems). Each sample was analyzed in triplicate wells with 30 ng of first-strand cDNA in a total reaction volume of 20 ml. The temperature profile consisted of 40 cycles of 15 s at 95 1C and 1 min at 60 1C. Data was analyzed with the comparative 2DDCt method using ribosomal 18S as endogenous control.
Metabolite determinations. To measure glycogen content, we scraped cell monolayers into 30% KOH and heated the extract for 15 min at 100 1C. We measured glycogen as described previously 42 . To assess glycogen branching, we used a previously described method based on the iodine absorption spectrum 33 . The intracellular concentration of G6P was measured by a spectrophotometric assay 43 .
Determination of MGS activity. Cell-culture plates were processed as described in the Supplementary Methods. Protein concentration was measured by the Bradford method 44 . MGS activity was measured in homogenates in the absence or presence of 6.6 mM G6P, as described previously 45 . The activity measured in the absence of G6P represents the active form of MGS (I or a form), whereas the activity measured in the presence of 6.6 mM G6P represents total MGS activity. The -G6P/+G6P activity ratio is a nonlinear measurement of the activation state of the enzyme. Values below 0.1 indicate an essentially fully inactive enzyme, whereas those above 0.7 are equivalent to full activation 46 .
Statistical analysis. Results were analyzed for significance by ANOVA and unpaired Student's t test. P o 0.05 was considered to be significant.
Note: Supplementary information is available on the Nature Neuroscience website.
